In a Nature Communications paper, the laboratory of Professor Jan Terje Andersen and collaborators report on a novel antibody constant region (Fc) variant that is designed to give antibodies broad biodistribution and make them long-acting in the body. This is particularly important for treatment of life-long chronic diseases and for prophylactic treatment of severe infections. In all cases, the pharmacokinetic profile of the antibody will guide dosing size and frequency, so as to secure high concentration of active antibody in blood